Shu-Chih Chen
Gründer bei ATOSSA THERAPEUTICS, INC.
Vermögen: - $ am 30.06.2024
Aktive Positionen von Shu-Chih Chen
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| ATOSSA THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 01.04.2009 | - |
| Gründer | 01.12.2008 | - | |
| Technik-/Wissenschafts-/F&E-Leiter | 01.04.2010 | - |
Karriereverlauf von Shu-Chih Chen
Ehemalige bekannte Positionen von Shu-Chih Chen
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| SC2Q Consulting Co. | Gründer | 01.01.2006 | 01.01.2008 |
| Präsident | - | 01.01.2008 | |
MDRNA, Inc.
 MDRNA, Inc. Miscellaneous Commercial ServicesCommercial Services MDRNA, Inc. engages in development and commercialization of innovative products based on proprietary molecular biology-based intranasal drug delivery technology. The company creates or utilizes novel formulation components or excipients that can transiently manipulate or open 'tight junctions' between cells in various tissues and thereby allow therapeutic drugs to reach the blood stream. The company is located in Hauppauge, NY. | Direktor/Vorstandsmitglied | 01.01.2002 | 01.01.2006 |
| Ensisheim Partners LLC | Präsident | 01.01.2008 | - |
| National Yang Ming University | Corporate Officer/Principal | - | - |
Ausbildung von Shu-Chih Chen
| Michigan State University | Doctorate Degree |
| National Yang Ming University | Undergraduate Degree |
Statistik
International
| Vereinigte Staaten | 6 |
| Taiwan | 2 |
Operativ
| Director/Board Member | 2 |
| Founder | 2 |
| President | 2 |
Sektoral
| Consumer Services | 3 |
| Health Technology | 2 |
| Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ATOSSA THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
| SC2Q Consulting Co. | |
| Ensisheim Partners LLC | |
MDRNA, Inc.
MDRNA, Inc. Miscellaneous Commercial ServicesCommercial Services MDRNA, Inc. engages in development and commercialization of innovative products based on proprietary molecular biology-based intranasal drug delivery technology. The company creates or utilizes novel formulation components or excipients that can transiently manipulate or open 'tight junctions' between cells in various tissues and thereby allow therapeutic drugs to reach the blood stream. The company is located in Hauppauge, NY. | Commercial Services |
- Börse
- Insiders
- Shu-Chih Chen
- Erfahrung
